Join us for our 10th anniversary of Outrun CF in Ajax!
We're catching up to a cure!Read More
Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the browsers below.
Cystic Fibrosis Canada has transformed the way it receives advice from the research and healthcare community. These exciting changes will see improved opportunities for participation and enhanced engagement among our stakeholders across Canada’s universities and hospitals where Cystic Fibrosis Canada funded research and care are taking place.
For the first time in the history of Cystic Fibrosis Canada, the involvement of scientists and healthcare professionals in supporting the work of our organization will be structured within our organizational design through the creation of the Research Advisory Council and the Healthcare Advisory Council. In addition, Scientific Review Panels are in place to undertake peer reviews of grant and award applications.
Composed of a cross-section of scientists from across the country along with lay members, the Research Advisory Council will provide input on the development of new research programs and initiatives in an advisory capacity to management, and advise on the approaches required to successfully implement the organization’s strategic directions and business plan specific to research. The Research Advisory Council will consider issues where scientific input is required, and will provide stewardship of the peer review framework for research funding. Based upon advice from Scientific Review Panels, this body will make recommendations on the approval of Cystic Fibrosis Canada grants, awards and other research funding initiatives.
The purpose of the Healthcare Advisory Council is to provide advice and recommendations to Cystic Fibrosis Canada’s management on the implementation of healthcare programs and quality improvement initiatives. Made up of healthcare professionals and lay members, the Healthcare Advisory Council will advise on the programs required to successfully implement the organization’s strategic directions and business plan specific to CF care quality improvement. This body will also consider issues where specialized input is required such as infection control and latest advances in clinical care.
The Board of Directors has also established a Scientific Advisory Committee to provide independent scientific advice on strategic policy formulation and input into research funding priorities. Members of this advisory committee shall not be current recipients of funding from Cystic Fibrosis Canada, nor shall they not be permitted to seek funding from Cystic Fibrosis Canada during their term of office.
Ms. Karen Corraini, British Columbia
Dr. Charles Deber, Ontario
Ms. Anna Gravelle, British Columbia
Dr. John-Paul Heale, British Columbia
Mr. Stuart Hodge, Ontario (Board Rep)
Dr. Larry Lands, Quebec (Chair)
Dr. Maggie McIlwaine, British Columbia
Dr. Michael Parkins, Alberta (Vice Chair)
Mr. Max Pinsky, British Columbia
Dr. Bradley Quon, British Columbia
Dr. Rémi Rabasa-Lhoret, Quebec
Dr. Nick Simmonds, United Kingdom
Mr. Wally Speckert, Ontario
Dr. David Thomas, Quebec
Dr. Kathryn Deuchars, Ontario (Board Rep)
Dr. Mark Chilvers, British Columbia (Chair)
Mr. Daniel Cortes, Ontario
Dr. Patrick Daigneault, Quebec
Ms. Karen Doyle, Newfoundland
Ms. Ena Gaudet, Ontario
Mr. Alexandre Grégoire, Quebec
Dr. Annick Lavoie, Quebec
Ms. Sandy Stevens, Alberta
Dr. Pamela Valentine, Alberta (Board Rep)
Dr. Valerie Waters, Ontario (Vice Chair)
Cystic Fibrosis Canada is grateful to these individuals for agreeing to serve the organization in this volunteer opportunity. These appointments are for three-year terms effective February 1, 2014. We look forward to their contribution over the coming years.